The FDA recently approved the C3-specific compstatin derivate Pegcetacoplan (brand name Empaveli) for treatment of PNH (41), which underscores C3 as a feasible therapeutic target. The gene discussed is C3; the disease is paroxysmal nocturnal hemoglobinuria.